Sign inJoin waitlistJoin the waitlist

Portell

Hematology & Oncology · University of Virginia Physicians Group

Credentials: · · ·

History

Saint Louis University School of Medicine
2006

Research

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Blood · 2018 · 298 citations
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Blood · 2020 · 267 citations
Postibrutinib outcomes in patients with mantle cell lymphoma
Blood · 2016 · 259 citations

Brian Hill
12 papers
BK
Brad Kahl
11 papers
Jonathon Cohen
11 papers
Manali Kamdar
11 papers
Michael Williams
11 papers
Reem Karmali
10 papers
Krista Isaac
9 papers · 6 as a fellow
Izidore Lossos
8 papers
Peter Martin
8 papers
VO
Victor Orellana-Noia
8 papers · 5 as a fellow
Andrew Evens
7 papers
Adam Olszewski
6 papers

Grants

A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients with Relapse or Refractory Periperal T-Cell Lymphoma (PTCL).
Food and Drug Administration · R01
Contact PI · $808.7K · University of Virginia
2020–2027

Clinical trials

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Principal investigator · Recruiting · Phase 2
University of Virginia
2021–2030
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
Study chair · Completed · Phase 2
PrECOG, LLC.
2020–2024
Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy
Study chair · Completed · Phase 2
PrECOG, LLC.
2017–2023
Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL
Study chair · Completed · Phase 1
Craig Portell, MD
2015–2021